TEAD Inhibitor Compounds for Isoform Selectivity and Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TEAD inhibitors lack selectivity, leading to undesirable effects such as toxicity and cancer cell proliferation, and existing therapies for TEAD-mediated diseases like cancer are not optimized for specific TEAD isoforms.
Innovation Solution
Development of compounds that selectively bind TEAD isoforms, particularly TEAD1 and TEAD4, to inhibit abnormal transcriptional activity, thereby treating diseases characterized by TEAD hyperactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective TEAD inhibitors are used, then broad TEAD activity inhibition is achieved, but toxicity and off-target effects increase
Solution Approach 1:
The patent segments the TEAD inhibitor portfolio by developing compounds with selective affinity for specific TEAD isoforms (TEAD1, TEAD2, TEAD3, or TEAD4). This is achieved through structural modifications in the compound formulas (I) and (I') that enable differential binding to isoform-specific regions, allowing inhibition of pathogenic isoforms while sparing protective ones.
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at defined positions in the compound structures (e.g., R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100) to modulate isoform selectivity. These localized structural changes confer specific binding properties to particular TEAD isoforms.
2Object-affected harmful factors
If selective TEAD inhibitors are developed, then off-target effects are reduced, but compound complexity increases
Solution Approach 1:
The patent employs a universal scaffold structure (formula I and I') that can accommodate multiple substituent variations while maintaining core TEAD-binding activity. This multi-functional platform allows generation of isoform-selective inhibitors through systematic modification of substituent groups, enabling broad coverage of TEAD isoforms from a single core structure.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying physical and chemical properties of substituent groups (e.g., hydrophobicity, electronegativity, steric bulk, hydrogen bonding capacity) at different positions in the molecule. These parameter modifications tune the binding affinity and selectivity profile toward specific TEAD isoforms while maintaining overall inhibitor efficacy.
3Reliability
If TEAD1 and TEAD4 are selectively targeted, then therapeutic efficacy in cancer is enhanced, but development complexity increases
Solution Approach 1:
The patent applies dynamics by creating a series of compounds with graded selectivity profiles that can be optimized for TEAD1/TEAD4 preference. The structural formulas allow dynamic adjustment of selectivity through substituent selection, enabling progression from broad-spectrum inhibitors to highly isoform-selective agents with enhanced therapeutic windows.
Solution Approach 2:
The patent uses specific substituent groups as intermediaries that mediate the interaction between the inhibitor and TEAD1/TEAD4 isoforms. These intermediary structural elements (e.g., specific aromatic rings, heterocyclic groups, alkyl chains at defined positions) facilitate selective binding to isoform-specific pockets while maintaining affinity for the conserved TEAD-binding interface.
Data Source
AI summary
The present disclosure provides, in part, compounds of formula (I), wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, such as proliferative disorders, mediated by TEA domain transcription factors.